Last update 21 Nov 2024

GEH-200521(18F)

Overview

Basic Info

Drug Type
Diagnostic radiopharmaceuticals
Synonyms
Target-
Mechanism
PET imaging(Positron-emission tomography enhancers)
Therapeutic Areas
Neoplasms
Active Indication
Malignant Solid Neoplasm
Inactive Indication-
Originator Organization
GE Healthcare B.V.
Active Organization
GE Healthcare Technologies, Inc.GE Healthcare Technologies, Inc.GE Healthcare Holdings, Inc.
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

3
Clinical Trials associated with GEH-200521(18F)
NCT06398730 / RecruitingPhase 1
A Phase 1, Single-Center, Open-Label, Single-Arm, Dose-Escalation, Positron Emission Tomography Study to Assess the Safety and Tolerability, Immunogenicity, Pharmacokinetics, Dosimetry and Biodistribution Following GEH200521 (18F) Injection Co-Administered With GEH200520 Injection in Healthy Volunteers
NL-OMON53493 / RecruitingNot Applicable
A Phase 1a/1b, Multi-Centre, Open-Label, Dose-Escalation and Dose-Expansion Study in Patients with Solid Tumour Malignancies to Evaluate GEH200520 Injection / GEH200521 (18F) Injection Safety and Tolerability, Positron Emission Tomography Imaging, Pharmacokinetics, and Changes in Imaging after Treatment - GEH200520/GEH200521(18F) used for PET scans in patients with solid tumors
NCT05629689 / RecruitingPhase 1
A Phase 1a/1b, Multi-Centre, Open-Label, Dose-Escalation and Dose-Expansion Study in Patients With Solid Tumour Malignancies to Evaluate GEH200520 Injection / GEH200521 (18F) Injection Safety and Tolerability, PET Imaging, Pharmacokinetics, and Changes in Imaging After Treatment
100 Clinical Results associated with GEH-200521(18F)
Login to view more data
100 Translational Medicine associated with GEH-200521(18F)
Login to view more data
100 Patents (Medical) associated with GEH-200521(18F)
Login to view more data
100 Deals associated with GEH-200521(18F)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Malignant Solid NeoplasmPhase 1
NL
GE Healthcare Holdings, Inc.
27 Jan 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free